#dasabuvir

Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.

Individuals who have failed hepatitis C treatment may ultimately achieve a cure if they add Sovaldi (sofosbuvir) to a subsequent treatment reg...

AbbVie has applied for FDA approval of a new formulation of its hepatitis C treatment Viekira Pak that requires once-daily dosing instead...

AbbVie’s Viekira Pak cured 95% of people with geno 1 of hepatitis C in a study of the long-term post-cure progression of liver disease.

An ongoing real-world study of Viekira Pak has shown that the drug apparently treats genotype 1 of hepatitis C as well as it did in clinical t...

Two new treatments have hit the market, offering more options for those with genotypes 3 and 4, while another new regimen for multiple genotyp...

The interview went to air today and I’ve included a link. The only thing I’m not happy with? The photo. It’s awful.

AbbVie’s single-tablet combination regimen Technivie plus ribavirin to treat genotype 4 among those without cirrhosis is approved.

Once you’ve officially rid yourself of hepatitis C, how certain can you be that the virus is gone for good?

Harvoni and the combination of Sovaldi and daclatasvir were the least likely to cause a severe reaction with the HIV regimens of a cohort of H...

The World Health Organization (WHO) has added the new hepatitis C medications to its Model List of Essential Medicines.

AbbVieâ€™s Viekira Pak, with or without ribavirin, appears to work very well curing genotype 1 of hepatitis C.

I picture my Hepatitis C medication as waging war against the virus in my system. Do you see your treatment in any particular light? Or is it...

So I thought I’d keep a treatment journal of sorts, for myself mainly, but also anyone else who might be starting this journey.

BMS has resubmitted an application to the FDA for approval of daclatasvir, this time in combination with Sovaldi (sofosbuvir), to treat genoty...

Clinicians treating people with hepatitis Cappear more likely to keep them adherent to the medications if they add a personal touch to care, t...